
PAX
Patria Investments Ltd
Financial Services
Patria Investments Ltd (PAX) Stock News
The latest PAX headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Pharmaceuticals announced completion of patient enrolment in the IPAX-2 Phase 1 study of TLX101-Tx (¹³¹I-iodofalan) for newly diagnosed glioblastoma. The study reached its maximum dose of 10GBq with no dose-limiting toxicities observed. The company is also advancing the pivotal IPAX BrIGHT Phase 3 trial for recurrent glioblastoma, marking the first radiopharmaceutical therapy to enter Phase 3 development for this indication.